02 Nov New Shingles Vaccine Available
Following the FDA approval in October of Shingrix (Zoster Vaccine Recombinant, Adjuvanated), GSK announced the CDC’s Advisory Committee on Immunization Practices (ACIP) recommends Shingrix as the preferred vaccine for the prevention of shingles for adults aged 50 and up. The new recommendation means up to 62 million more adults in the US should be immunized (approximately 42 million aged 50-59 years old and 20 million who have previously been vaccinated against shingles).
As a PAA member, your practice has access to contract pricing on Shingrix. Contact us to learn how to enroll. Call 866-348-9780 or send an email to membership@physall.com.
